ArticleLeukemia2008
Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis.
Article in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01261429 (Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Tenosynovial giant cell tumor involving the cervical spine: A case report.World journal of clinical cases · 2021Article
- Immunotherapy Targeting Tumor-Associated Macrophages.Frontiers in medicine · 2020Review
- Tenosynovial giant cell tumor of the cervical spine: a case report.Spinal cord series and cases · 2019Article
- Article
- BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?TH open : companion journal to thrombosis and haemostasis · 2018Review
- Progress in tumor-associated macrophage (TAM)-targeted therapeutics.Advanced drug delivery reviews · 2017Review
- Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.Current treatment options in oncology · 2016Review
- Article
- Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib.Clinical sarcoma research · 2013Article
- Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.Journal of bone and mineral metabolism · 2012Article
- The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines.PloS one · 2011Article
- Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.Leukemia · 2010Article
- Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.Sarcoma · 2010Article
- Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.Journal of experimental & clinical cancer research : CR · 2009Review
- Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro.Leukemia · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.